US FDA Grants RMAT Requests At Similar Rate To Breakthrough Designations

 
• By Bridget Silverman
Regenerative medicine
RMAT designees are slower to receive full FDA approval than those with breakthrough therapy designations. • Source: Alamy

More from Review Pathways

More from Pathways & Standards